Study identifier:NIS-CFR-CRE-2007/2
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Observational usage study of statins in primary care in France
Healthy
-
Yes
-
All
2100
Observational
N/A
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Dec 2014 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
To describe the way statins are used in France in primary care, that is to determine patients profile (particularly CV risk factors), to determine the way statins are initiated by general practitioners, to evaluate aftercare and to assess patients treated by rosuvastatin
Location
Location
Changsha, Hunan, China
Location
Chengdu, Sichuan, China
Location
Chongqing, Chongqing, China
Location
Fuzhou, Fujian, China
Location
Guangzhou, Guangdong, China
Location
Hangzhou, Zhejiang, China
Location
Hefei, Anhui, China
Location
Jinan, Shandong, China
Arms | Assigned Interventions |
---|---|
1 Patients to whom a statin was initiated or switched between 3 and 6 months before consultation | - |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.